NIH Director's Blog: Drug Discovery

APRIL 11, 2017

Caption: Cyclic peptide (middle) binds to iPGM (blue). Credit: National Center for Advancing Translational Sciences, NIH When you think of the causes of infectious diseases, what first comes to mind are probably viruses and bacteria. But parasites are another important source of devastating infection, especially in the developing world.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

Codon

APRIL 9, 2023

Read Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Nature Cell Biology. Read The Engineering Biology Research Consortium released a report on both technical achievements and barriers to progress in the bioeconomy. McGrady N.R. Nature Methods.

Therapies 52

Therapies RNA Engineering Vaccine 52

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Read A really simple way to isolate AAVs, which are a type of virus often used to deliver gene therapies into cells. An open-source FACS automation system for high-throughput cell biology. Gene Therapy.

DNA 52

DNA RNA Engineering Licensing 52

Codon

APRIL 30, 2023

This works for many different cell types, and the method can also be used to deliver several different gene editors at once. It’s an easier way to get CRISPR into cells! Other methods to deliver Cas9 (like with viruses) are way less efficient, and seem to vary wildly from one cell to the next. Nature Cell Biology.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

This works for many different cell types, and the method can also be used to deliver several different gene editors at once. It’s an easier way to get CRISPR into cells! Other methods to deliver Cas9 (like with viruses) are way less efficient, and seem to vary wildly from one cell to the next. Nature Cell Biology.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 16, 2023

Compact gene editors , called enOsCas12f1 and enRhCas12f1, are smaller than many existing Cas proteins and can thus be more easily delivered in a single virus for gene therapies. By engineering the sgRNA and optimizing these proteins, new variants had high editing efficiencies and low off-target effects in human cells. Cell Reports.

Engineering 52

Engineering DNA RNA Science 52